DRTS is technically overbought after a strong run that has already reached its V8 price target, compounded by a four-quarter earnings miss streak and modest insider selling, leaving negative risk/reward asymmetry.
Thesis pillars
- Overbought Momentum Run↓Deteriorating
- Four Quarter Earnings Miss Streak↓Deteriorating
- Negative Risk Reward Asymmetry↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026
Alpha Tau Medical Ltd. (DRTS) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.35: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for... Read more
Sell if holding. Engine safety override at $13.35: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 21d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Alpha Tau Medical Ltd.
Latest news
- NEWS Alpha Tau Medical and Samsung Medical Center Sign MOU for Pancreatic Cancer Clinical Trial — fiscal.ai Oct 22, 2026 positive
- NEWS Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer — benzinga Oct 22, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target — benzinga Oct 20, 2026 positive
- NEWS Alpha Tau Medical Receives FDA Approval to Expand REGAIN Clinical Trial — fiscal.ai Oct 19, 2026 positive
- NEWS Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study — benzinga Oct 19, 2026 positive
Generated 2026-10-29T11:48:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.35: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $12.42. Score 4.8/10, moderate confidence.
Analyst target: $15.49 (+16.0% upside). Prior stop was $12.42. Stop-loss: $12.42.
Quality below floor (1.5 < 4.0).
Alpha Tau Medical Ltd. trades at a P/E of N/A (forward -25.0). TrendMatrix value score: 7.5/10. Verdict: Sell.
11 analysts cover DRTS with a consensus score of 4.2/5. Average price target: $18.
What does Alpha Tau Medical Ltd. do?Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and...
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.